Ocugen is a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. It is headquartered in Malvern, Pennsylvania.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Ocugen news
08.05.2022
Ocugen's GAAP loss for 3 months of 2022 was $18.019 million, up 2.6 times from $7.077 million in the previous year.
Source: 
ir.ocugen.com
ir.ocugen.com
04.03.2022
FDA has denied FDA approval of Ocugen's emergency use of COVAXIN to prevent COVID-19 in persons aged 2 to 18 years. The company will continue to work with the FDA to evaluate the regulatory mechanism for pediatric use of the drug.
Source: 
ocugen.gcs-web.com
ocugen.gcs-web.com
26.11.2021
The FDA has suspended clinical trials of BBV152, the COVID-19 vaccine from Ocugen known outside the United States under the brand name COVAXIN. The regulator will report specific trial shortcomings and instructions on how to correct them at a later date.
Source: ocugen.gcs-web.com
ocugen.gcs-web.com
09.11.2021
Ocugen's GAAP loss for 9M 2021 was $43.784 million, up 2.4 times from $18.032 million in the prior year.
Source: ir.ocugen.com
ir.ocugen.com
General information
| Company name | Ocugen |
|---|---|
| Tags | #biotechnology, #genome |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 263 Great Valley Parkway Suite 160 Malvern, PA 19355 United States |
| Mailing address | 263 Great Valley Parkway Suite 160 Malvern, PA 19355 United States |
| Website | ir.ocugen.com |
English (US) 